

UTAH Diabetes Data & Forecasts

State Total Population Forecasts	2015	2020	2025	2030
Entire Population	2,783,000	2,990,100	3,225,700	3,485,400
Prediabetes	690,000	765,800	850,900	920,600
Diagnosed diabetes	141,600	180,200	218,600	255,100
Undiagnosed diabetes	66,200	80,000	92,100	101,800
Total with diabetes (diagnosed and undiagnosed)	207,800	260,200	310,700	356,800
Complications:				
Visual impairment	23,200	28,700	33,800	38,300
Renal failure	340	410	490	550
Leg amputations	290	340	380	410
Annual deaths attributable to diabetes	1,530	1,850	2,130	2,360
Total annual cost (2015 dollars)	\$1.9 B	\$2.4 B	\$2.8 B	\$3.2 B
Annual medical costs	\$1.5 B	\$1.8 B	\$2.1 B	\$2.4 B
Annual nonmedical costs	\$0.4 B	\$0.6 B	\$0.7 B	\$0.8 B

State Senior Population Forecasts	2015	2020	2025	2030
Population 65 and older	281,000	341,100	405,500	460,600
Prediabetes	143,300	174,000	206,800	234,900
Diagnosed diabetes	53,100	64,500	76,600	87,000
Undiagnosed diabetes	19,700	23,900	28,400	32,200
Total with diabetes (diagnosed and undiagnosed)	72,800	88,300	105,000	119,300
Complications:				
Visual impairment	9,900	11,700	13,600	15,100
Renal failure	160	190	220	240
Leg amputations	120	140	150	160
Annual deaths attributable to diabetes	1,050	1,240	1,390	1,490
Total annual cost (2015 dollars)	\$0.9 B	\$1.1 B	\$1.3 B	\$1.5 B
Annual medical costs	\$0.8 B	\$1.0 B	\$1.2 B	\$1.4 B
Annual nonmedical costs	\$0.1 B	\$0.1 B	\$0.1 B	\$0.1 B

These forecasts are based on the latest available national diabetes data, including U.S Census Bureau population projections, the CDC National Diabetes Statistics Report, 2014, CDC diabetes morbidity trend reports, CDC's latest diabetes prevalence projections to 2050 and Dall, et al. "The Economic Burden of Elevated Blood Glucose Levels in 2012: Diagnosed and Undiagnosed Diabetes, Gestational Diabetes Mellitus, and Prediabetes," *Diabetes Care* 2014;37:3172-3179. These forecasts assume a steady, but conservative, reduction in the number of people with complications due to better awareness of the risks of diabetes, earlier screening and intervention, and more effective therapies.

For details and references on the Institute for Alternative Futures Diabetes 2030 Forecasting Model Methodology, visit www.altfutures.org/diabetes2030.

Research funded by Novo Nordisk Inc.